View Cart  

Acute Heart Failure Drug Trials Should Include Co-Primary Endpoints, EMA Says

Developers of acute heart failure drugs should conduct double-blind, randomized Phase III trials with co-primary endpoints, rather than composite endpoints, according to a European Medicines Agency (EMA) draft guideline.

To View This Article:


Subscribe To International Pharmaceutical Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00